Research programme: small molecule therapeutics - C4X Discovery

Drug Profile

Research programme: small molecule therapeutics - C4X Discovery

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator C4X Discovery
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor agonists; Genome modulators; Glucagon like peptide 1 receptor agonists; Interleukin 17 receptor antagonists; KEAP1 protein modulators; NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer; Chronic obstructive pulmonary disease; Inflammation; Neurodegenerative disorders; Type 2 diabetes mellitus

Most Recent Events

  • 28 Sep 2016 C4X Discovery and Evotec agree to co-develop small molecule therapeutics
  • 06 Sep 2016 C4XD and Structural Genomics Consortium agree to co-develop small molecule therapeutics in United Kingdom for Cancer
  • 06 Sep 2016 C4X discovery has patent protection for Conformetrix technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top